NewYork-Presbyterian cancer specialists are at the forefront of expanding and innovating treatment for everything from breast cancer to glioblastoma. In 2025, our physicians and researchers from Columbia and Weill Cornell Medicine improved progression-free survival for multiple types of cancer, employed artificial intelligence to inform clinical care, discovered biomarkers that predict treatment responses to help personalize care in complex cases, and more. These advancements are breaking ground for new solutions that can improve cancer outcomes for all patients.
Through two world-class cancer centers – Columbia’s NCI-designated Herbert Irving Comprehensive Cancer Center and Weill Cornell Medicine’s Meyer Cancer Center, our team of physician-scientists are transforming care for cancer patients across a broad spectrum of malignant diseases and conditions. From pursuing novel laboratory research to better predict, diagnose and treat cancer, to conducting clinical trials of promising new therapies, our physicians provide personalized treatment plans to deliver optimal outcomes.
Oncology (Cancer)
Stay up to date with the latest in Oncology
The NYP Advances newsletter delivers groundbreaking research and advancements straight to your inbox.
Featured Updates
Neurology & NeurosurgeryCerebral Organoids Provide New Strategy to Personalize Glioblastoma Treatment
Cerebral Organoids Provide New Strategy to Personalize Glioblastoma Treatment
On this episode of Advances in Care, Erin Welsh is joined by Dr. Howard Fine, a neuro-oncologist at NewYork-Presbyterian and director of the Brain Tumor Center at Weill Cornell Medicine, to explore his pioneering research on glioblastoma, the most common and aggressive form of brain cancer.
Podcast
Episode 48
Stay up to date with the Advances newsletter
Get the latest groundbreaking research and advancements in medicine delivered to your inbox.
